Condition: Metastatic Colorectal Cancer · Sponsor: Dominik Paul Modest
FIRE-8 is a prospective, randomized, open label, multicenter phase II clinical trial. To evaluate the effecacy of trifluridine / tipiracil and panitumumab (Arm A) compared to trifluridine / tipiracil and bevacizumab (Arm B), participants will be randomly assigned to either Arm A or Arm B for the treatment of metastatic colorectal cancer. The primary objectives of this study is to compare the effecacy of treatment with trifluridine / tipiracil plus panitumumab versus trifluridine / tipiracil plus bevacizumab.
This description comes directly from the study's public registry record.
Dominik Paul Modest, Prof. · +49 30 450 553840 · dominik.modest@charite.de
Sebastian Stintzing, Prof. · +49 30 450 513002 · sebastian.stintzing@charite.de
Always discuss trial participation with your own doctor first.
| Charité - Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05007132